Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
President Donald Trump has consistently demonstrated a preference for maintaining control over escalation rather than allowing events to dictate American strategy.
The summits are not endpoints. They are the mechanism by which two countries, which can neither resolve their differences nor afford to rupture them, manage the interval between crises.